Prognostic Value of Hemodynamic Indices Prior to tMCS Explantation: An Analysis from the Cardiogenic Shock Working Group.
Mar 2, 2026DOI: 10.1016/j.cardfail.2026.02.019Journal ArticleJCF
Written by: Christian SaidJaime Hernandez-MontfortJonas SundermeyerSong LiRachna KatariaElric ZweckAnthony FaugnoShashank S SinhaJacob AbrahamManreet K KanwarArthur Reshad GaranVAN-Khue TonClaudius MahrPaavni SangalPeter NatovM Imran AslamDaniel BurkhoffNavin K KapurCARDIOGENIC SHOCK WORKING GROUP ACADEMIC RESEARCH CONSORTIUM
Advanced Heart Failure · Saint Francis Health System
Summary
BACKGROUND: Standardized hemodynamic-guided weaning criteria are needed for patients with cardiogenic shock receiving temporary mechanical circulatory support (tMCS). We aimed to determine whether hemodynamic indices prior to tMCS explant predict mortality and native heart survival and whether performance varies across device platforms.METHODS: We analyzed 385 cardiogenic shock patients from the multicenter Cardiogenic Shock Working Group registry who received tMCS. Four indices were evaluated: blood pressure response index (BPRI), organ perfusion pressure (OPP), aortic pulsatility index (API), and modified API (mAPI). The primary outcome was in-hospital mortality; the secondary outcome was native heart survival. Multivariable models were adjusted for age, sex, and device type. Receiver operating characteristic (ROC) curves assessed discrimination, restricted cubic splines examined nonlinear relationships, and device-stratified analyses evaluated platform-specific performance.RESULTS: BPRI demonstrated the highest area under the curve (AUC) for mortality (AUC, 0.786) and native heart survival (AUC, 0.747) compared with OPP (0.711), mAPI (0.654), and API (0.600). Survivors demonstrated BPRI improvement (8.4-18.2), whereas nonsurvivors showed stagnation (4.7-5.2). Each 10-point BPRI increase was associated with a 46% mortality reduction (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.42-0.68; P < .001). BPRI remained strongly associated with lower mortality across device platforms, including Impella (OR, 0.24; 95% CI, 0.10-0.58; P = .001) and the intra-aortic balloon pump (OR, 0.65; 95% CI, 0.48-0.90; P = .008).CONCLUSION: Pre-explant BPRI demonstrated the highest prognostic accuracy for mortality and native heart survival across multiple tMCS platforms.
JH
Dr. Jaime Hernandez Montfort
Cardiology · Advanced Heart Failure & TransplantationSaint Francis Health Systemjaimeh